 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...

GeoVax to Participate in Upcoming December Investor Events

Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA...

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

HC Wainwright reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX  Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a $8.00...

GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at HC Wainwright

GeoVax Labs, Inc. (NASDAQ:GOVX  Free Report)  Analysts at HC Wainwright cut their FY2023 earnings per share (EPS) estimates for shares of GeoVax Labs in a research note issued on...

GeoVax Labs, Inc. to Post FY2023 Earnings of ($1.03) Per Share, HC Wainwright Forecasts (NASDAQ:GOVX)

Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GeoVax Labs reports Q3 EPS (32c), consensus (24c)

Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck...

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023...

Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing...

GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Watchers	12,142
52-Wk Low	$0.405
52-Wk High	$1.39

Market Cap	$11.05M
Volume (M)	499,710.00
52-Wk High	$1.39
52-Wk Low	$0.405

GOVX Geovax Labs Inc

About

Feed

News

Earnings

Fundamentals